Healing & recovery
A lab-made copy of a natural heart hormone (BNP) that eases fluid overload and improves blood flow during acute heart failure.
Start here
Nesiritide is a lab-made copy of BNP, a hormone the heart releases when it is under strain. It is FDA approved for acute heart failure and is given by IV in the hospital, where it relaxes blood vessels, helps the body shed extra fluid, and eases shortness of breath within minutes 5.
Nesiritide is synthetic B-type natriuretic peptide (BNP) that helps failing hearts work better. It relaxes blood vessels, reduces fluid volume, and helps the heart pump more efficiently—a powerful intervention for acute heart failure.
Nesiritide is recombinant BNP (a lab-made copy of B-type natriuretic peptide, a heart hormone). It activates natriuretic peptide receptors, which raises cGMP (a signaling chemical inside cells). This relaxes blood vessels (vasodilation (widening blood vessels)), makes the kidneys pass more sodium (natriuresis), and lowers aldosterone secretion (aldosterone is a hormone that makes the body hold onto salt and water). It reduces cardiac preload (the amount of blood filling the heart) and afterload (the pressure the heart pumps against) while improving cardiac output (the amount of blood the heart pumps).
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Rapid Symptom Relief
Works quickly: in the VMAC trial, 60% of its 3-hour drop in lung pressure came within 15 minutes of the starting dose, and breathlessness improved more than with placebo at 3 hours.
Fluid Management
Lowers the filling pressures that push fluid into the lungs. In VMAC, where diuretics were allowed, the net fluid removed over the first 24 hours (about 1.25 L) was the same as with nitroglycerin.
Heart Workload Reduction
Relaxes veins and arteries, lowering the pressures the heart works against: lung wedge pressure, right atrial pressure and pulmonary artery pressure all fell significantly versus placebo at 3 hours in VMAC.
The most-asked question
The research-reported range is 0.01 mcg/kg/min, once daily. Studies used different doses for different situations — find yours:
Acutely decompensated heart failure, Dyspnea at rest
2 mcg/kg given as one quick dose into a vein (IV bolus)
FDA-approved Natrecor loading bolus given before the maintenance infusion 56. May be omitted if hypotension risk is high.
Acutely decompensated heart failure, Reduction of pulmonary capillary wedge pressure
0.01 mcg/kg/min as a continuous drip into a vein
FDA-approved maintenance infusion following the bolus 56. Hospital-only with continuous blood-pressure monitoring.
The ceiling: 0.03 mcg/kg/min (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Nesiritide (BNP):
Add the recommended volume of bacteriostatic water to the Nesiritide (BNP) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Nesiritide (BNP) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Nesiritide (BNP)'s recorded schedule.
Timing
Nesiritide (BNP) is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
IV administration of Nesiritide (BNP) is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
Nesiritide (BNP) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Headache, reported in 7% of patients versus 6% on placebo during the first 24 hours of infusion 5.
What to do Usually resolves as body adjusts; pain relievers can help if needed
Feeling dizzy or faint, typically mild and temporary 5
What to do Sit or lie down until it passes; inform your medical team if persistent
Minor discomfort in the back area during or after treatment 5
What to do Usually improves on its own; stretching may help
Worth knowing about, but most people never see these.
Blood pressure falls too far. This is the most common and dose-limiting side effect: 12% of patients versus 4% on placebo during the first 24 hours of long infusions 5.
What to do Medical team monitors closely; may adjust dosage or add supportive fluids
Stomach or belly discomfort unrelated to the underlying condition
What to do Notify medical team; usually resolves quickly
Difficulty sleeping during treatment period
What to do Typically temporary; avoid caffeine and establish good sleep routine
Rare, but if any of these happen, stop and contact a medical professional.
Kidney function can worsen. In VMAC, creatinine rose more than 0.5 mg/dL above baseline by day 30 in 28% of nesiritide patients versus 21% on nitroglycerin, so creatinine is monitored during and after treatment 5.
What to do Requires immediate medical attention and kidney function monitoring
Dangerous drop in blood pressure requiring emergency intervention 5
What to do Emergency medical care needed; discontinue immediately and provide supportive therapy
Rare but serious immune response including difficulty breathing or swelling 5
What to do Seek emergency care immediately; stop medication and provide antihistamines/epinephrine
Week by week
Is it right for you?
Nesiritide (BNP) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Combined effect can cause dangerous dehydration and kidney injury; must be carefully monitored
Risk of dangerously low blood pressure; requires careful dosage adjustment and monitoring
Nesiritide-related kidney effects may be worsened; avoid if possible during treatment
A water pill (loop diuretic) that helps the body remove fluid; nesiritide makes it work better by improving blood flow to the kidneys
Works well alongside nesiritide's widening of blood vessels; both reduce the heart's workload and improve blood flow
Another drug that widens blood vessels; the two work together to ease strain on the heart and improve blood flow to tissues
Generally safe to take alongside Nesiritide (BNP). Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 5.
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 5.
Nesiritide's benefit is short-term: it lowers lung pressures and eases breathlessness in the first hours of treatment 5. In the 7,141-patient ASCEND-HF trial it did not reduce 30-day death or heart-failure rehospitalization (9.4% vs 10.1%), and it is not recommended for routine use 25.
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nesiritide (Natrecor) was FDA-approved for acutely decompensated heart failure (a sudden worsening of heart failure) with breathlessness at rest or with minimal activity 5. Low blood pressure is the dose-limiting side effect: 12% of patients versus 4% on placebo in long-infusion trials, and symptomatic low blood pressure in 7.1% versus 4.0% in the 7,141-patient ASCEND-HF trial 25. When it happens it can last longer than with nitroglycerin (mean 2.2 vs 0.7 hours), because the blood-pressure effect outlasts the drug's 18-minute half-life (how long it stays active in your body) 5. Serum creatinine (a blood marker of kidney strain) rises more often than with placebo or nitroglycerin, so kidney function is monitored during and after treatment 5. A pooled analysis of seven trials found no increase in 30- or 180-day mortality, and the trials showed no sign of tachyphylaxis (the body getting used to the drug so it works less) 5.
FDA approval rested on the VMAC trial (489 patients), which compared nesiritide with placebo and IV nitroglycerin. At 3 hours nesiritide lowered pulmonary capillary wedge pressure (a measure of pressure backed up in the lungs) by 5.8 mmHg (vs 2.0 with placebo and 3.8 with nitroglycerin) and improved breathlessness more than placebo 5. It acts on guanylate cyclase receptors (receivers in blood-vessel walls) to raise cGMP (an internal signal that relaxes vessels), widening veins and arteries; in animals it did not change how hard the heart contracts 5. The later ASCEND-HF trial (7,141 patients) found only a small, non-significant improvement in breathlessness and no reduction in 30-day death or heart-failure rehospitalization, and concluded nesiritide cannot be recommended for routine use in acute heart failure 2.
Keeping it good
Store Nesiritide (BNP) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Nesiritide (BNP) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2002
Nesiritide was developed as a recombinant B-type natriuretic peptide (a heart hormone made by genetic engineering), given into a vein, for acute decompensated heart failure (a sudden worsening of heart failure). The FDA approved the drug in August 2001, marking a breakthrough in acute heart failure management.
Burger AJ, et al.
2011
N Engl J Med 2011;365:32-43 (PMID 21732835). ASCEND-HF randomly assigned 7,141 people hospitalized with acute heart failure to nesiritide or placebo. Shortness of breath improved slightly (6 h: 44.5% vs 42.1%; 24 h: 68.2% vs 66.1%) but missed the preset bar for statistical significance. There was no difference in death or heart-failure rehospitalization within 30 days (9.4% vs 10.1%) or in worsening kidney function (31.4% vs 29.5%), and low blood pressure was more frequent. The authors concluded nesiritide cannot be recommended for routine use in the broad acute heart failure population.
O'Connor CM, Starling RC, Hernandez AF, et al.
2005
Critical review raised questions about nesiritide's long-term benefits despite its short-term improvements in blood flow and pressure (hemodynamics). Safety concerns and limited evidence that it reduces deaths led to ongoing evaluation of its clinical role.
Topol EJ
2008
Despite controversy over long-term outcomes, nesiritide remains useful for rapid symptom relief in acute heart failure. Ongoing research clarifies its optimal use, patient selection, and role in modern heart failure management.
Burnett JC Jr, Korinek J
2019
Natrecor is no longer listed on DailyMed or openFDA and the accessdata label PDF no longer resolves, so this cites RxList's copy of the label (revised Jan 2019). Indicated for acutely decompensated heart failure (a sudden worsening of heart failure) with shortness of breath at rest or with minimal activity; it lowered PCWP (pulmonary capillary wedge pressure, a measure of pressure in the lungs' blood vessels) and improved shortness of breath at 3 hours. Dosing: 2 mcg/kg IV bolus (one quick dose into a vein) then 0.01 mcg/kg/min. In the VMAC trial, 60% of the 3-hour PCWP reduction occurred within 15 minutes of the bolus. Low blood pressure (hypotension) limits how much can be given (12% vs 4% placebo); headache 7% vs 6%. Half-life is 18 minutes. Worsening kidney function: creatinine (a kidney blood test) more than 0.5 mg/dL above baseline in 28% (Natrecor) vs 21% (nitroglycerin) through day 30 in VMAC.
U.S. Food and Drug Administration / Scios (reproduced by RxList)
2008
Circulation: Heart Failure perspective on nesiritide (recombinant human B-type natriuretic peptide, a lab-made human heart hormone) — its approval for acute decompensated heart failure (a sudden worsening of heart failure), the later controversy over its safety, and its prospects.
Burnett JC Jr, Korinek J
If this isn't the right fit
Your questions
Nesiritide is one of the fastest-acting heart failure medications. Most patients notice improvement in breathing within 5-15 minutes of receiving the initial bolus dose. About 60% of the medication's effect is usually achieved within 15 minutes, and 95% within one hour. This rapid action makes it ideal for emergency situations.
No. Nesiritide must be administered intravenously by medical professionals in a hospital, emergency room, or specialized infusion center. It requires continuous monitoring of your heart rate, blood pressure, and kidney function. The medication cannot be given by injection under the skin or taken by mouth.
Low blood pressure is one of the most common side effects. Your medical team actively monitors this and can adjust the dose, slow the infusion rate, or add extra fluids through an IV to raise your blood pressure back up. In most cases, they can manage this by adjusting the nesiritide dose without stopping it entirely.
Nesiritide can occasionally cause a temporary decline in kidney function, especially in patients with existing kidney problems. This is why your medical team checks kidney function before, during, and after treatment. The good news is that nesiritide's kidney effects are usually reversible once the medication is stopped. Your doctor will decide if nesiritide is appropriate for you based on your kidney function.
Nesiritide is unique because it's the only medication that's a recombinant copy of your body's natural BNP hormone. It works faster than most oral heart medications and provides relief within minutes rather than days or weeks. However, it only works intravenously in acute settings, whereas drugs like ACE inhibitors can be taken at home long-term. Nesiritide is designed for emergency crisis management, not ongoing maintenance therapy.
No. Nesiritide provides temporary relief of acute symptoms but doesn't cure heart failure or repair the underlying heart damage. Think of it as a lifeline during a crisis. After the acute episode improves, you'll need to take other long-term medications and make lifestyle changes to manage your heart condition going forward.
Nesiritide is designed for short-term acute use, typically during a hospital stay. Most patients receive it for 24-72 hours. It's not appropriate for long-term home use. After stabilization, you'll transition to oral medications and follow-up with your cardiologist.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Nesiritide (BNP) research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek